Nanofibrous patches for targeted therapy of cutaneous leishmaniasis caused by Leishmania major: a preclinical amphotericin B platform.

ABSTRACT: Cutaneous leishmaniasis (CL) remains a significant public health challenge in endemic regions, particularly where access to safe and patient-friendly treatments is limited. Amphotericin B (AmB), although highly active against Leishmania, is restricted by systemic toxicity and the need for parenteral administration. In this study, AmB-loaded bioactive nanofibrous patches were fabricated using a dual-nozzle electrospinning method incorporating chitosan, gelatin, and polyvinyl alcohol. The resulting nanofibers were structurally characterized by scanning electron microscopy, Fourier-transform infrared spectroscopy, and X-ray diffraction. Drug loading was uniform, and in vitro release demonstrated a sustained profile with approximately 82% cumulative release at 72 h. Cytocompatibility was confi

SUBMITTER: Allahmoradi M 

PROVIDER: S-EPMC12698821 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature